<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01422590</url>
  </required_header>
  <id_info>
    <org_study_id>2010-04-071</org_study_id>
    <nct_id>NCT01422590</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin</brief_title>
  <official_title>Pharmacodynamics After Concomitant Administration With Mitiglinide and Sitagliptin Compared to Mitiglinide, Sitagliptin Single Administration in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Explore pharmacodynamics

             -  glucose

             -  insulin

             -  C-peptide

             -  glucagon

             -  intact GLP-1

             -  DPP-4 activity

             -  CGMS (continuous glucose monitoring system)

        2. Assess Safety

             -  adverse events

             -  clinical laboratory test

             -  physical examination
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacodynamic assessment

        -  CGMS data is obtained from day 1 to day 3 (48 hours)

        -  PD is measured before (day 1) and after drug administration (day 2)

             1. AUC of glucose, insulin, C-peptide, glucagon, intact GLP-1, DPP-4 activity

             2. MAGE (mean amplitude of glycemic excursion) from CGMS data
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (area under the curve) of plasma glucose</measure>
    <time_frame>day 1 and day 2 of each period</time_frame>
    <description>Differences of AUC before treatment (day 1) and after treatment (day 2) is compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of insulin</measure>
    <time_frame>day 1 and day 2 of each period</time_frame>
    <description>Differences of AUC before treatment (day 1) and after treatment (day 2) is compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of intact GLP-1</measure>
    <time_frame>day 1 and day 2 of each period</time_frame>
    <description>Differences of AUC before treatment (day 1) and after treatment (day 2) is compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of C-peptide</measure>
    <time_frame>day 1 and day 2 of each period</time_frame>
    <description>Differences of AUC before treatment (day 1) and after treatment (day 2) is compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of glucagon</measure>
    <time_frame>day 1 and day 2 of each period</time_frame>
    <description>Differences of AUC before treatment (day 1) and after treatment (day 2) is compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MAGE</measure>
    <time_frame>day 1 and day 2 of each period</time_frame>
    <description>Differences of MAGE before treatment (day 1) and after treatment (day 2) is compared between treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of DPP-4 activity</measure>
    <time_frame>day 1 and day 2 of each period</time_frame>
    <description>Differences of AUC before treatment (day 1) and after treatment (day 2) is compared between treatment groups</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitiglinide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin + Mitiglinide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Single oral administration of sitagliptin 100 mg</description>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitiglinide</intervention_name>
    <description>Single oral administration of mitiglinide 10 mg</description>
    <arm_group_label>Mitiglinide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin, Mitiglinide</intervention_name>
    <description>Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg</description>
    <arm_group_label>Sitagliptin + Mitiglinide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with type 2 diabetes mellitus

          -  6.5% ≤ HbA1c &lt; 9.0%

          -  Stopped treatment of sulfonylurea and biguanide for more than 8 weeks

          -  Stopped treatment of other anti-diabetic agents for more than 12 weeks

          -  16 kg/m2 ≤ body mass index &lt; 30 kg/m2

        Exclusion Criteria:

          -  Fasting glucose ≥ 200 mg/dL

          -  Required insulin therapy

          -  Patients with neuropathy, retinopathy or renopathy

          -  Contraindicated for mitiglinide or sitagliptin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wooseong Hur, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2011</study_first_submitted>
  <study_first_submitted_qc>August 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2011</study_first_posted>
  <last_update_submitted>September 6, 2011</last_update_submitted>
  <last_update_submitted_qc>September 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sitagliptin</keyword>
  <keyword>mitiglinide</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitiglinide</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

